04 March 2022: Articles
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
Unusual setting of medical care
Takatsugu Ogata A , Yasuko Fujita B , Kei Muro A*DOI: 10.12659/AJCR.935600
Am J Case Rep 2022; 23:e935600
Figure 3. Gastric mucosal biopsy. (A) Hematoxylin-eosin staining before the rechallenge with trastuzumab deruxtecan (T-DXd): poorly differentiated adenocarcinoma. (B) HER2 immunohistochemistry (IHC) before the T-DXd rechallenge: score 2+. (C) HER2 dual-color in-situ hybridization (DISH) before the T-DXd rechallenge: HER2/chromosome 17 (Chr17) ratio, 3.76. (D) Hematoxylineosin staining after 4 cycles of T-DXd: poorly differentiated adenocarcinoma. (E) HER2 IHC after 4 cycles of T-DXd: score 2+. (F) HER2 DISH after 4 cycles of T-DXd: HER2/Chr17 ratio, 3.05.